Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure.

"We are pleased that the FDA has approved the protocol for this Phase III study of farletuzumab in first-relapsed, platinum-sensitive ovarian cancer," stated Martin D. Phillips, M.D., Chief Medical Officer of Morphotek. "Physicians and patients do not have many good choices for treating ovarian cancer at this stage, and we are hopeful that some day farletuzumab may provide an option for ovarian cancer patients and their caregivers."

Morphotek is currently concluding a Phase II trial with farletuzumab as a single-agent and in combination with standard-of-care chemotherapy (carboplatin and taxane) in platinum-sensitive ovarian cancer patients experiencing a first relapse of their disease. The trial was designed to measure objective rate of response, and to compare the length of a patient's second remission with her first remission. Interim results from the study demonstrated an encouraging rate of durable objective response in patients on combination therapy. These findings prompted pursuit of a definitive pivotal study to evaluate the capacity of farletuzumab to benefit patients with ovarian cancer in a rigorously controlled manner.

The Phase III study, the design of which was agreed to by FDA, will assess the capacity of farletuzumab to extend progression free survival and overall survival in combination with carboplatin and taxane at two different dose levels of farletuzumab. The study will be conducted as a randomized, double-blind, plac
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Buenos Aires, Argentina: Yoga classes ( clases de ... Argentina by the Sivananda Yoga Vedanta Center. The ... (Barrio Norte). Classes are 90 minutes and are offered ... in a calm environment, allowing visitors to enjoy the ... food, among others. , The Yoga classes follow the ...
(Date:5/19/2013)... Boca Raton, FL (PRWEB) May 19, 2013 ... have launched the website YazSideEffects.com in a concerted effort ... effects of the combination birth control drugs Yaz, Yasmin ... website offers a wealth of information on the notorious ... about lawsuits against Bayer Pharmaceuticals. , Yaz, Yasmin ...
(Date:5/18/2013)... Daily Gossip issued a press release last ... their page. John Colston, Daily Gossip’s spokesperson, told the press ... 14-Day Rapid Fat Loss Plan . , Shaun ... healthy at a time when nutritionists and fat loss gurus ... , The diet is based on the Macro-Patterning ...
(Date:5/18/2013)... 2013 Also known as bariatric ... weight loss surgery that guarantees patients long-term weight loss. ... wishes to give readers a brief tutorial on this ... school at New York City’s Mount Sinai School of ... undertook a fellowship in Minimally Invasive Bariatric Surgery. He ...
(Date:5/18/2013)... swallow high-powered magnets often need surgery and other invasive ... study. The researchers, from the Louisiana State University ... 79 percent of children who swallowed very strong "neodymium ... which a tube containing a camera is inserted into ... can be treated through observation or by pumping the ...
Breaking Medicine News(10 mins):Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2
... 25, 2010 (Toronto) A new study from The Centre ... accounts for 43% of all cigarettes consumed by Ontario high ... The study, published in the current edition of Tobacco ... and found that of high school daily smokers, 50% smoked ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Oct. 22 ... Staphylococcus aureus , or MRSA, a common bacterial infection acquired ... presented at the annual meeting of the Infectious Diseases Society ... of the people it infected within 30 days, the study ...
... DETROIT Patients admitted to the hospital for the ... a first line of defense with the potent antibiotic ... according to a Henry Ford Hospital study. For ... whether vancomycin or so-called B-lactam antibiotics like penicillin or ...
... Reporter , FRIDAY, Oct. 22 (HealthDay News) -- You might have seen ... an Iraq War vet with severe burns across much of his body ... his injuries. Martinez, 27, earned the right to play that role ... month into his first Iraq deployment as a real-life Army soldier, his ...
... School of Medicine, led by Lucila Ohno-Machado, MD, PhD, ... Department of Medicine, have received two federal grants totaling ... gather, analyze, use and share vast, ever-increasing amounts of ... over five years will create a national center for ...
... new cancer research being released at the American Society for ... 31 through November 4, 2010, in San Diego. For ... Napoli at nicolen@astro.org or Beth Bukata at ... 1:00 p.m. Eastern time. Adding radiation to hormone ...
Cached Medicine News:Health News:Contraband cigarettes main source of supply for Ontario youth 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 3Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 2Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 3Health News:UC San Diego receives 2 major biomedical informatics grants 2Health News:UC San Diego receives 2 major biomedical informatics grants 3Health News:UC San Diego receives 2 major biomedical informatics grants 4Health News:Practice-changing studies on how oncologists treat cancer to be presented at ASTRO Annual Meeting 2
(Date:5/17/2013)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... today announced that it will release its unaudited financial results ... on Tuesday, May 28, 2013.  The Company will host a ... EDT (May 28, 2013 at 8:00 p.m. China Standard Time) ... on recent corporate developments. To access the conference ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... May 16, 2013  Today, the National Patient Advocate ... House of Representatives recently approved a bill that ... charging patients higher out-of-pocket fees for newer, more expensive ... which have more severe side-effects. However, the bill was ... which will continue to be a barrier to patients ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: